ViroGates is an international medical technology company headquartered in Denmark and since June 2018 listed on Nasdaq First North Growth Market, Denmark (Ticker code: VIRO).

We aim to be perceived as a trustworthy and open company and will communicate all information correctly, in a balanced, transparent and timely way and simultaneously to investors, equity analysts and other stakeholders in the financial markets to facilitate regular trading and fair pricing of the company’s shares.

Investment highlights

  • In commercialization phase with approved product portfolio with strong patents
  • EUR ~250 million initial market potential with short-term focus on European Acute Care – Global value of addressable Acute Care market EUR +1 billion
  • Cash at hand sufficient to lead to profitability
  • Almost 40 hospitals in eight countries in Europe currently using the Company’s products
  • Significant clinical data, documentation and 550 peer reviewed articles to support the value of suPAR

Strategic objectives

  • 40 paying hospital accounts by the end of 2020
  • Cash flow positive by the end of 2020

 

Read Announcements

Latest Reports

 

 

Contact Investor Relations
CEO Jakob Knudsen
Tel. +45 2113 1336
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Jungmansgatan 12
211 19 Malmö
Tel. (+46) 40 200 250
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.